Abzena is the leading end-to-end bioconjugate, Antibody-drug conjugate (ADC), and complex biologics CDMO + CRO. From early discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development and manufacture of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions, like our next generation site-specific conjugation technology, ThioBridge™, that’s been proven to improve the safety, efficacy, and potency of ADCs and bioconjugates. The company has research, development, and stateof-art cGMP facilities with high potency handling capabilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK- thus enabling us to move medicines forward faster and with greater success.